Driehaus Capital AMLX Position
Active12-Fund ConvergenceDriehaus Capital increased their position in Amylyx Pharmaceuticals, Inc. (AMLX) in Q4 2025, holding $37.6M worth of shares across 3,109,503 shares.
The position was first reported in Q2 2025 and has been tracked across 3 quarterly 13F filings.
AMLX is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 13.6% of float with 14.7 days to cover, indicating significant bearish positioning against Driehaus's long thesis.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
13.6%
14.7 days to cover
Driehaus Capital AMLX Position History
Frequently Asked Questions
Does Driehaus Capital own AMLX?
Yes. As of Q4 2025, Driehaus Capital holds 3,109,503 shares of Amylyx Pharmaceuticals, Inc. (AMLX) valued at $37.6M. This data comes from their SEC 13F filing.
How many hedge funds own AMLX?
12 specialist biotech hedge funds currently hold AMLX, including Perceptive Advisors, Boxer Capital, Commodore Capital and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy AMLX?
Driehaus Capital's position in AMLX was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's AMLX position increasing or decreasing?
Driehaus Capital increased their AMLX position in the most recent quarter, adding 688,736 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AMLXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →